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Nax is the sodium-level sensor of body fluids in the
brain involved in sodium homeostasis. Nax-knockout
mice do not stop ingesting salt even when dehy-
drated. Here we report a case with clinical features
of essential hypernatremia without demonstrable
hypothalamic structural lesions, who was diagnosed
as a paraneoplastic neurologic disorder. The patient
had autoantibodies directed against Nax, along with
a ganglioneuroma composed of Schwann-like cells
robustly expressing Nax. The removal of the tumor
did not reduce the autoantibody levels or relieve
the symptoms. Intravenous injection of the immuno-
globulin fraction of the patient’s serum into mice
induced abnormalities in water/salt intake and
diuresis, which led to hypernatremia. In the brains
of these mice, cell death was observed along with
focal deposits of complement C3 and inflammatory
infiltrates in circumventricular organs where Nax is
specifically expressed. Our findings thus provide
new insights into the pathogenesis of hypernatremia
relevant to the sodium-level-sensing mechanism in
humans.
INTRODUCTION
Sodium (Na) homeostasis is crucial for life, and Na levels in body
fluids are constantly monitored in the brain (Andersson, et al.,
1982). Appropriate responses to an elevation of the serum Na
level are greater water intake stimulated by thirst and minimum
excretion of concentrated urine caused by the secretion of anti-
diuretic hormone (ADH; vasopressin) (Votey et al., 1989). If these
regulatory mechanisms are impaired, Na levels in body fluids
should be chronically increased. Hypernatremia, defined as
a rise in the plasma Na concentration to a value exceeding the
physiological level (145 mM), is a common electrolyte disorder508 Neuron 66, 508–522, May 27, 2010 ª2010 Elsevier Inc.(Lin et al., 2005; Baylis and Thompson, 1988), withmortality rates
ranging from approximately 40% to more than 60% (Palevsky,
1998).
‘‘Essential hypernatremia’’ is clinically characterized by
upward resetting of both the osmotic set point for vasopressin
release and the threshold for thirst perception, resulting in persis-
tent hypernatremia with a euvolemic state (Avioli et al., 1962;
DeRubertis et al., 1974;Welt, 1962).Usually, structural abnormal-
ities in the hypothalamic-pituitary area, as a result of trauma,
tumors, or inflammation, are detected. However, several cases
of essential hypernatremia without demonstrable hypothalamic
structural lesions have been reported, although the precise
mechanism or mechanisms have not been elucidated (Bappal
et al., 2006; Cauble et al., 2001; Conley et al., 1976; duRivage
et al., 1985; Hayek and Peake, 1982; Schaad et al., 1979).
We previously reported, based on a battery of studies on Nax-
knockout (Nax-KO) mice, that Nax channel is the Na-level sensor
of body fluids in the brain (Hiyama et al., 2002, 2004; Noda, 2006,
2007; Noda and Hiyama, 2005; Watanabe et al., 2000). Nax is an
atypical Na channel whose structure is poorly homologous to the
voltage-gated Na channels (Goldin et al., 2000) that is expressed
in the posterior pituitary and three circumventricular organs
(CVOs) in the brain: the subfornical organ (SFO), organum vascu-
losum of the lamina terminalis (OVLT), and median eminence
(ME) (Watanabe et al., 2000, 2006). The Nax channel is a concen-
tration-sensitive Na channel with a threshold value of 150 mM
for the extracellular Na ion (Hiyama et al., 2002).Nax-KOmice do
not stop ingesting salt when dehydrated, whereaswild-type (WT)
mice avoid salt (Hiyama et al., 2004; Watanabe et al., 2000).
Unlike in WT mice, salt-aversive behavior does not occur upon
the direct infusion of a hypertonic Na solution into the cerebral
ventricle in Nax-KO mice (Hiyama et al., 2004). The abnormal
salt intake pattern of Nax-KO mice was rescued by a site-
directed transfer of the Nax gene with an adeno-viral vector
into the SFO (Hiyama et al., 2004). These findings obtained
withNax-KOmice led us to speculate that there could be patients
with hypernatremia whose Na-level sensory system is impaired
for some reason.
In the present paper, we report a patient with essential hyper-
natremia who developed autoantibodies to Nax. The patient had
Neuron
Autoimmunity to Na Sensor Causes Hypernatremiaa ganglioneuroma that was mainly composed of Nax-positive
Schwann-like cells, and this neoplasia likely evoked an antitumor
immune response. Passive transfer of the immunoglobulin (Ig)
fraction of the patient’s serum reproduced her symptoms with
abnormal reductions in water intake and vasopressin-release
in WT mice, most likely due to the complement-mediated cell
death in the CVOs where Nax is expressed. Her symptoms
thus suggest a paraneoplastic neurologic disorder (PND) char-
acterized by neurologic dysfunction in the setting of a remote
cancer. Our study shows, for the first time, that autoimmunity
to the Na-level sensor Nax causes chronic hypernatremia.
RESULTS
A Patient with Adipsic Hypernatremia
A 6.5-year-old Asian girl was admitted to Tokai University
Hospital because of general fatigue and fluctuating drowsiness
persisting for a week. Past history revealed no perinatal prob-
lems, with a birth weight of 2940 g at 41 weeks of gestation.
No developmental delay was noted. Her growth was unremark-
able except for obesity. Physical examination on admission
revealed a rather chubby-looking girl (115 cm [+0.2 SD] in height,
29.6 kg [+2.3 SD] in weight), with normal blood pressure (110/
70 mmHg), tachycardia (132 beats/min), prompt capillary refill-
ing, and normal skin turgor. She had no pretibial pitting edema.
No clinical evidence of severe dehydration was noted. Clinical
features of precocious puberty were absent. Neurological exam-
ination revealed a slightly impaired consciousness, a score of 1
(awake without any stimuli, and almost fully conscious) on the
Japan Coma Scale, normal muscular tonus, no muscular weak-
ness, and no sensory disturbances. We found that she had
marked hypernatremia with a serum Na concentration as high
as 199 mM (Figure 1A, day 1). Of note, she did not complain of
any thirsty sensation despite such extreme hypernatremia.
The results of clinical tests are summarized in Table S1 in the
Supplemental Information (available online). Blood urea nitro-
gen, creatinine, and albumin levels were elevated, along with
the marked elevation of her serum Na concentration, suggesting
dehydration to some extent, although this was hardly detectable
by physical examination. Endocrinological tests were unremark-
able except for vasopressin, prolactin, and plasma renin activity.
Notably, her vasopressin level of 2.1 pg/ml should be interpreted
as rather low, considering her serum Na concentration of
199 mM. A slight elevation in the concentration of prolactin
is insufficient for the diagnosis of prolactinoma, in which the
serum prolactin level usually exceeds 100 ng/ml. Thyroid func-
tion was normal. Hypernatremia due to Cushing’s syndrome or
primary aldosteronism was ruled out, because cortisol and
adrenocorticotropic hormone (ACTH) levels were within the
normal range, and her aldosterone level was low. Urinalysis
revealed the following: pH 5.0, specific gravity 1.038, protein
(1+), occult blood (–), and glucose (–). The fractional excretion
of Na was 1.34%.
Clinical Treatments for the Patient
Intravenous infusion therapy (day 1–8) with a series of hypotonic
fluids resulted in a gradual decrease in her serum Na concentra-
tion without the development of convulsions (Figure 1A); theclinical course and compositions of the fluids are shown in
Figure S1 (available online) and in the ‘‘Intravenous Infusion in
the Patient’’ subsection in the Supplemental Information. Her
serumNa concentration was 142mMon day 8, with concomitant
decreases in hematocrit (31.2%), creatinine (0.4 mg/dl), and
blood urea nitrogen (17 mg/dl) values, and with a slight increase
(1.0 kg) in body weight. Along with the decrease in her serum
Na concentration, her creatine phosphokinase level and platelet
count were normalized to 89 IU/l and 21.83 104/ml, respectively,
on day 10. The proteinuria disappeared on day 2. Although her
urine output before admission was unknown, her urine volume
during the initial 4 hr of fluid therapy starting on admission
was 125 ml (i.e., 1.05 ml/kg/hr). Her urine volume thereafter
was also kept substantial, around 700 to 1000 ml/day (mean
845 ml/day).
Abdominal ultrasonography and magnetic resonance imaging
(MRI) revealed a solid tumor adjacent to the right adrenal gland.
The retroperitoneal tumor was surgically removed on day 14
(Figure 1B), on the assumption that the tumor was somehow
related to her extreme hypernatremia. The histological diagnosis
of the retroperitoneal tumor was ganglioneuroma, composed of
abundant Schwann-like cells along with some ganglion cells
(Figure 1C).
For the surgery, the patient again received infusions from day
14 to 20 and her serum Na level was stabilized in the normal
range (Figure 1A, day 16–20). However, when the infusion was
discontinued, her serum Na level slightly increased again
(156mMonday 27; 155mMonday 31). Resumption of the hypo-
tonic infusion from day 35 to 37 decreased the serum Na
concentration to the normal level; however, stopping the infusion
reproducibly resulted in an increase (161 mM on day 44). From
day 44, the patient was instructed to drink 1000–1500ml of water
per day (day 44–78), and her serum Na level became relatively
stable in the range of 145–155 mM (day 46–78). We placed the
patient on ad libitum water intake from day 79, and she stayed
home on days 81 and 82. This caused an elevation in her Na level
to 162 mM (day 84), indicating that the serum Na level highly
depends on water intake and that the patient’s hypernatremia
was not cured by the removal of the tumor. Then we again
instructed the patient to drink a sufficient amount of water from
day 84. After leaving the hospital on day 106, the patient has
been directed to drink 1500–2000 ml of water/day. However,
her serum Na level continues to fluctuate even now, 4 years after
removal of the tumor (Figure 1D).
Tests to Delineate the Pathological Condition
and Etiology
To investigate whether an inadequate urine-concentrating ability
could be an underlying etiology of the persistent hypernatremia,
a vasopressin loading test and a fluid deprivation test were
performed 3 and 11months after the surgery, respectively. Intra-
nasal administration of 10 mg of a vasopressin analog, 1-dea-
mino-8-arginine-vasopressin (dDAVP), resulted in an increase
in urinary osmolality from 348 to 708 mOsm in 6 hr. Further,
her urine osmolality was 847 mOsm after overnight fluid depriva-
tion (16 hr), and with an additional 4 hr fluid deprivation (i.e., 20 hr
in total) it reached 1009mOsm, indicating that the urine-concen-
trating ability of the patient’s kidney was intact. Again, she didNeuron 66, 508–522, May 27, 2010 ª2010 Elsevier Inc. 509
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Figure 1. A Patient Suspected of Having Essential Hypernatremia with Impaired Vasopressin Release
(A) Fluctuation in the serum Na level of the patient in the hospital. Day 1 indicates the day the patient was admitted to the hospital. The patient received fluid
infusions during the time periods indicated by the blue lines. The volumes and the Na levels of fluids are presented in Figure S1. The patient underwent surgery
to remove the ganglioneuroma on day 14. Instructions regarding the amount of water to drink (green and red lines) were suspended from day 79 to 83 and the
patient stayed home from day 81 to 82.
(B) Whole image of the removed ganglioneuroma tissue. Scale bar, 5 mm.
(C) Hematoxylin eosin staining of a section of the ganglioneuroma. Round-shaped ganglion cells (arrows) are surrounded by Schwann-like cells.
(D) Serum Na level of the patient after her discharge from the hospital. The abscissa indicates month/year from the day the patient was admitted to the hospital. I,
II, and III indicate the days when the sera used for experimental analyses were collected. The total IgG concentration in the patient’s sera was 12.65, 11.05, and
10.64 (mg/ml) for serum I, II, and III, respectively.
(E) Relationship between the serum osmolality and plasma vasopressin level obtained during a 4-year follow-up of the patient. The green area indicates the
normal range.
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Autoimmunity to Na Sensor Causes Hypernatremianot complain of thirst during the fluid deprivation test. She
remained obese even after the surgery, with a tendency toward
hyperphagia and hyperhidrosis. The hyperhidrosis may con-
tribute to the loss of free water in this patient.510 Neuron 66, 508–522, May 27, 2010 ª2010 Elsevier Inc.To examine the possibility of inadequate vasopressin release,
the relationship between serum osmolality and the plasma vaso-
pressin level obtained during a 4-year follow-up was plotted
(Figure 1E). The data clearly showed that a normal increase of
Neuron
Autoimmunity to Na Sensor Causes Hypernatremiavasopressin secretion in response to serum hyperosmolality is
lacking in this patient. Impaired secretion of vasopressin, along
with adipsia, was considered to have greatly contributed to the
development of persistent hypernatremia. Adipsia, hypernatre-
mia, obesity, and disrupted vasopressin secretion led us to diag-
nose the patient as having essential hypernatremia, synonymous
with adipsic hypernatremia or hypodipsia-hypernatremia syn-
drome (Avioli et al., 1962; DeRubertis et al., 1974; Welt, 1962).
In most cases of essential hypernatremia reported to date,
significant intracerebral pathology was present, with presumed
damage to the relevant hypothalamic regions. However, we
could not detect a structural anomaly such as a space-occu-
pying lesion within the brain of the patient by MRI, with special
concerns in the hypothalamus and pituitary gland (Figure S2),
suggesting essential hypernatremia without demonstrable intra-
cranial structural lesions.
Serum of the Patient Contains Autoantibodies to Nax
The marked increase in the serum Na level without any feeling
of thirst or Na aversion suggested functional defects in the
Na-level-sensing mechanism in the brain. In her clinical records
1 year before her admission to the hospital, when the patient was
referred to a local clinic because of obesity, her plasma Na level
was normal (138 mM). Because her parents and only brother
have no history of hypernatremia, it was unlikely that she had
some genetical problem. Indeed, there existed no significant
mutations in the exons by genomic sequencing covering 25
exons of the Nax gene of the patient (data not shown). Instead,
because she was harboring a retroperitoneal tumor, we sus-
pected that the generation of an autoantibody against the
Na-level sensor or osmotic sensor impaired the mechanism of
monitoring the condition of body fluids.
To test this idea, we developed a C6 rat glioblastoma cell line,
C6H17, in which the expression of human Nax channels is induc-
ible under the control of the tetracycline-responsive element
(TRE). In this cell line, Nax expression is induced by a transactiva-
tor, Tet-Off, which is transfected and expressed with an adeno-
viral vector. The membrane extracts of the cells were subjected
to western blotting with the patient’s serum taken at the time
point of 8 months after the admission to the hospital (indicated
by an arrow marked with I in Figure 1D). A band around
200 kDa, the appropriate size for Nax, was specifically detected
in the extract of the cells expressing Nax (Figure 2A, left, +). This
signal was absent in the extract of the cells without Nax expres-
sion (Figure 2A, left, –). When the membrane was reprobed with
control human serum, no band was detected (Figure 2A, right).
We further tested 10 serum samples from age- and sex-matched
control subjects, but all were negative for anti-Nax (data not
shown), strongly suggesting that the presence of the autoanti-
body to Nax is a specific feature of this patient.
The patient’s antibody could also detect mouse Nax
(Figure 2B), but not human Nav1.7, the Na channel most closely
related to Nax structurally (Figure S3). Thus, the epitope recog-
nized by the patient’s autoantibody was considered to be
common to human and mouse Nax, but not widely shared by
the members of the sodium-channel family. Besides the
Na-level-sensing mechanism, TRPV1 and TRPV4 were recently
suggested to be involved in osmosensing mechanisms of bodyfluids (Bourque, 2008; Liedtke, 2008), but neither anti-TRPV1
nor anti-TRPV4 autoantibody was detected in the patient’s
serum (Figures 2C and 2D).
To identify the epitope region for the autoantibody, we next
performed immunoblotting against a peptide array spotted
with overlapping sequences corresponding to the extracellular
region of human Nax. The list of peptides is shown in Table S2.
The serum from the patient reacted strongly with two neigh-
boring spots containing an overlapping sequence (Figure 2E,
closed bar), located in the vicinity of the pore-forming region of
the third domain of Nax (Figure 2F, closed arrow). The serum
also reacted weakly with another set of neighboring spots
(Figure 2E, open bar), located in the vicinity of the pore-forming
region of the second domain of Nax (Figure 2F, open arrow).
The subclass of the autoantibody against Nax in the patient
was determined to be IgG1 by western blotting (Figure 2G). In
addition to the patient’s serum I, we later examined the other
two blood samples taken from the same hypernatremia patient
at the time points of II and III in Figure 1D. We found that these
sera still detect human Nax proteins on western blotting, though
the titer was not constant (Figure 2H). This was confirmed by
immunocytochemistry of C6H17 cells expressing human Nax
(data not shown).
The Tumor Removed from the Patient Is Positive for Nax
If the development of the neoplasia triggered the emergence
of the autoantibody, the tumor should contain cells strongly
expressing Nax. To test this notion, tissue sections of the
ganglioneuroma removed from the patient were examined with
the rabbit polyclonal anti-Nax, along with the expression of
a Schwann cell marker, S-100 (Figure 2I). The ganglioneuroma
was markedly positive for both Nax and S-100. The Nax signal
colocalized with the S-100 signal at the cellular level, indicating
that Schwann-like cells in the tumor express Nax.
We also examined the expression of Nax in other ganglioneur-
omas developed in the vicinity of the adrenal gland in three
independent patients without hypernatremia: one is shown in
Figure 2I and the other two are shown in Figure S4. S-100 was
positive in all of them, but Nax was negative, indicating that
abnormal Schwann cells in ganglioneuromas are usually defi-
cient in Nax expression. That is, Nax is irregularly expressed
in the ganglioneuroma of this patient with hypernatremia. This
coincidental occurance of the Nax-positive neoplasm and the
autoantibody against Nax in the same patient led us to suppose
that the hypernatremia of this patient is an unidentified pheno-
type of a PND.
The Autoantibodies Recognize the Native Form of Nax
Immunocytochemistry of C6H17 cells with or without the expres-
sion of human Nax using the patient’s serum indicated that the
autoantibodies react to the native form of Nax: intense signals
were observed in the plasma membrane of the cells only when
the expression of Nax was induced (Figure 3A; Patient serum I,
compare Nax + and –). The reactivity of the serum was com-
pletely abolished by preincubation with synthetic peptides con-
taining the identified epitopes of Nax (Figure 3A, Patient serum I,
Nax peptides), but not with scrambled peptides (Figure 3A,
Patient serum I, Control peptides), confirming the specificityNeuron 66, 508–522, May 27, 2010 ª2010 Elsevier Inc. 511
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Figure 2. Serum of the Hypernatremia Patient Contained Autoantibodies to Nax
(A) Western blot analysis of the membrane extracts of C6H17 cells with (+) or without (–) expression of human Nax using serum at a 1:5000 dilution from either the
patient with hypernatremia (Patient serum I, see Figure 1D) or a healthy human subject (Control serum).
(B) Western blot analysis of the membrane extracts of C6M16 cells with (+) or without (–) expression of mouse Nax.
(C and D) Western blot analyses of the extracts of HEK293 cells expressing (+) human TRPV1 (C) or TRPV4 (D), and of control cells without expression (–).
(E) Epitope mapping for the anti-Nax autoantibodies in the patient using a peptide array. Major signals were detected at spots #24 (VMNKSRCESLLF) and #25
(CESLLFNESMLW) indicated by a closed bar. Minor signals were at #18 (GEWVETLWDCME) and #19 (LWDCMEVAGQSW) with an open bar. They correspond
to the regions of Nax indicated by open and closed arrows, respectively, in (F). The peptides spotted on the array are shown in Table S2.
(F) Schematic illustration of human Nax. The red box with a closed arrow in the vicinity of the pore-forming region in domain III indicates the location of the amino
acid sequence overlapping between peptides #24 and #25. The red box with an open arrow indicates the location of the sequence of peptides #18 and #19.
P, putative pore-forming regions.
(G) The subclass of the autoantibodies to Nax. The membrane extract of C6H17 cells with (+) or without (–) expression of human Nax was analyzed using the
patient’s serum I as the primary antibody and anti-human IgM, IgG1, IgG2, IgG3, or IgG4 as the secondary antibody.
(H) Western blot analyses of the extracts of C6H17 cells with (+) or without (–) expression of Nax using the sera from the hypernatremia patient at the time point of I,
II, and III (see Figure 1D) at 1:1000 and 1:5000 dilutions.
(I) Expression of Nax (green) and S-100 (red) in the ganglioneuroma removed from the patient with hypernatremia. Nax expression was negative in a ganglioneur-
oma from a patient without hypernatremia (for additional controls, see also Figure S4). Scale bars, 100 mm.
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Autoimmunity to Na Sensor Causes Hypernatremiaof the autoantibodies to Nax. There was no staining in
C6H17 cells expressing Nax with the control serum (Figure 3A,
Control serum), nor with an additional 10 control sera (data not
shown).
We examined the effect of the binding of autoantibodies using
dissociated Nax-expressing SFO cells of WT mice. The cells
were incubated with the serum from the patient or serum from
a healthy subject for indicated times, and then fixed to examine512 Neuron 66, 508–522, May 27, 2010 ª2010 Elsevier Inc.the subcellular distribution of Nax by immunostaining with the
rabbit polyclonal anti-Nax antibody (Figure 3B). Nax was found
at the plasma membrane at first (Figure 3B, 0 min), as we previ-
ously reported (Shimizu et al., 2007). However, its distribution
gradually changed, moving into the cell upon incubation with
the patient’s serum in a time-dependent manner, but this was
not the case with the control serum (Figure 3B). The distribution
profiles indicated the intracellular translocation of Nax at 60 min
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Figure 3. The Patient’s Autoantibodies React with Nax-Positive Cells
(A) Immunostaining of C6H17 cells with (+) or without (–) expression of humanNax using the patient’s serum (Patient serum I), control serum from a healthy subject
(Control serum), or the patient’s serum preincubated with either two epitope peptides of Nax (Nax peptides) or two scrambled peptides (Control peptides). The
binding of the autoantibodies was detected with anti-human IgG. DIC, differential interference contrast images.
(B) Confocal images of Nax distribution in dissociated SFO cells with the patient’s serum. SFO cells were incubated with the serum of the control subject (Control
serum) or the patient (Patient serum I) for the time period indicated and were then immediately fixed. After permeabilization, Nax was detected with the rabbit
polyclonal anti-Nax antibody and Alexa-488-conjugated anti-rabbit IgG. DIC, differential interference contrast images.
(C) Fluorescence intensity profiles along the red or blue line in (B) at 60 min. The intensity is shown with an arbitrary unit. The position of the fluorescence shifted
from the membrane to the intracellular region upon treatment with the patient’s serum, but not upon treatment with control serum.
(D) Immunostaining of sagittal brain sections of WTmice andNax-KOmice with the patient’s serum. Positive signals were observed in the subfornical organ (SFO)
and the organum vasculosum of the lamina terminalis (OVLT) of the WT mice, but not those of the Nax-KO mice.
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Autoimmunity to Na Sensor Causes Hypernatremiaupon incubation with the patient’s serum, but not upon that with
the control serum (Figure 3C).
The Autoantibodies React with the Circumventricular
Organs
Because the patient’s antibodies also recognize mouse Nax
channels (Figures 2A and 2B), we next tried to establish an
animal model of the disease of this patient. Prior to the animal
study, we checked whether the autoantibody can bind to the
Nax-positive cells at the tissue level. When mouse brain sections
were immunostained with the patient’s serum, the SFO and
OVLT, representative sites expressing Nax, were specifically
stained in the sections of WT mice, but not those of Nax-KO
mice (Figure 3D). In addition to these sites, the ME and posterior
pituitary expressing Nax were immunostained again only in WT
mice (data not shown). The specific staining of Nax-positiveregions in the brain is also indicative of the specificity of autoan-
tibodies to Nax, because other members of voltage-gated
Na channels including Nav1.1, 1.2, and 1.3 are intensively
expressed in the brain (Beckh et al., 1989). Control experiments
using sera of age- and sex-matched control subjects (from 10
individuals) produced no detectable staining in brain sections
of WT mice (data not shown).
Intravenous Injection of the Patient’s Ig Fraction
Induces Hypernatremia in Mice
We examined the pathophysiological effects of the autoantibody
to Nax by intravenously injecting WT mice with the patient’s Ig
fraction. After 1 week, we found that themice took in significantly
less water than those given the vehicle or control Ig under
nonfeeding conditions (Figure 4A). To show that this effect
was caused by the anti-Nax autoantibody, we removed theNeuron 66, 508–522, May 27, 2010 ª2010 Elsevier Inc. 513
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Figure 4. Patient-Ig-Injected Mice Showed the Symptoms of Hypernatremia
(A) Water intake volumes during the dark period (12 hr) of mice injectedwith saline (Vehicle), the immunoglobulin (Ig) fraction of a healthy subject (Control Ig), or the
Ig fraction of the patient (Patient Ig). The same experiments were performed with the patient’s Ig fraction absorbed with either Nax peptides [Patient Ig (Nax-abs)]
or scrambled peptides [Patient Ig (Control-abs)]. The value obtained with Patient Ig (Control-abs) did not differ significantly from that obtained with the Patient Ig
(p = 0.83). **p < 0.01 (comparedwith Vehicle), ##p < 0.01 [comparedwith Control Ig or Patient Ig (Control-abs)], respectively, by two-tailed t test; data are themean
and SE (n = 8 for each).
(B and C) Plasma vasopressin levels (B) and urine volumes (C) under normal (Hydrated) and 24 hr dehydrated (Dehydrated) conditions. *p < 0.05 and **p < 0.01
(compared with Vehicle), #p < 0.05 and ##p < 0.01 [compared with Control Ig or Patient Ig (Control-abs)], by two-tailed t test; data are the mean and SE (n = 8 for
each).
(D) Strategy of the food preference test. Mice were injected with Vehicle or Ig preparations 7 days before the test (day –9) and housed under usual conditions
(day –9 to day –3). From day –2 to day 10, Na-depleted food and Na-repleted food were served, and the mice could take them ad libitum. The amount of drinking
water was restricted to 0.5 ml/day from day 0 to 3.
(E) Preference ratios for Na-repleted food. *p < 0.05 (compared with Vehicle), #p < 0.05 and ##p < 0.01 (compared with Control Ig), by two-tailed t test; data are the
mean and SE (n = 8 for each).
(F) Preference ratios for Na-repleted food. #p < 0.05 [compared with Patient Ig (Control-abs)], by two-tailed t test; data are the mean and SE (n = 8 for each).
(G) Plasma Na levels of the mice at day 0, 3, 4, 5, and 10 in (E) and at day 3 and 10 in (F). *p < 0.05 and **p < 0.01 (compared with Vehicle), #p < 0.05 and ##p < 0.01
[compared with Control Ig or Patient Ig (Control-abs)], by two-tailed Mann-Whitney test; data are the mean and SE (n = 4 for each).
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with Nax-epitope peptides (Figures 2E and 2F). After adequate
absorption of the autoantibody (Figure S5), the depleted
patient’s Ig preparation was almost ineffective [Figure 4A,
Patient Ig (Nax-abs)], whereas the preparation absorbed with
control peptides remained effective [Figure 4A, Patient Ig
(Control-abs)].
Because the patient showed an abnormal reduction in vaso-
pressin release (Figure 1E), the plasma vasopressin level of the
mice was examined under hydrated (water-satiated) and dehy-
drated conditions. No differences were found among the three
groups under hydrated conditions (Figure 4B, Hydrated). After
24 hr of dehydration, the vasopressin level of the mice injected
with the patient’s Ig was elevated but significantly lower than
that of the mice given the vehicle or control Ig (Figure 4B, Dehy-
drated). Consistent with this finding, the amount of urine of the
patient-Ig-injected mice during 24 hr of dehydration was signifi-
cantly larger than that of the mice given the vehicle or control Ig
(Figure 4C, Dehydrated). The absorption of the anti-Nax autoan-
tibodies eliminated the ability to affect urine upon dehydration
(Figure 4C, Dehydrated).
We know that Nax-KO mice do not stop ingesting salt when
dehydrated (Watanabe et al., 2000; Hiyama et al., 2004). There-
fore, we examined the effect of the patient’s Ig on salt intake
behavior: the mice treated were allowed free access to both
normal (Na-repleted) and Na-depleted food under conditions
where the amount of drinking water was restricted to 0.5 ml/day
(Figure 4D). Before water was restricted, each group of mice
showed almost the same preference for normal andNa-depleted
food (Figures 4E and 4F, day 2, 1, and 0). During the water
restriction, the mice that received the vehicle, the control Ig, or
the patient’s Ig absorbed with the Nax peptides [Patient Ig
(Nax-abs)] progressively showed a preference for Na-depleted
food (Figures 4E and 4F, day 2 and 3). In contrast, those that
received the patient’s Ig (Patient Ig) or received the patient’s Ig
absorbed with the control peptides [Patient Ig (Control-abs)] did
not show such a normal behavioral response (Figures 4E and
4F, day 2 and 3).
After water restriction for 3 days, the plasma [Na+] reached
over 160 mM in the groups given Patient Ig or Patient Ig
(Control-abs), while it remained at a physiological level in those
given vehicle, control Ig, or Patient Ig (Nax-abs) (Figure 4G,
day 3). On repletion with enough water, the preference for
Na-depleted food of the groups given vehicle, control Ig, or
Patient Ig (Nax-abs) recovered to the normal level within 1 day
(Figures 4E and 4F, day 4), and importantly, their plasma [Na+]
remained at the basal level during the test (Figure 4G, day 4).
In contrast, the groups given Patient Ig or Patient Ig (Control-
abs) showed slightly but significantly higher levels of [Na+] in
plasma even 1 week after water repletion (Figure 4G, day 10).
High Plasma Na+ Levels by Excessive Salt Intake
in the Two-Bottle Test
We confirmed the abnormality in salt intake with another exper-
imental strategy using a two-bottle test with pure water and
hypertonic saline (Figure 5A): 1 week after the intravenous
injection with the patient or control Ig, the mice underwent the
two-bottle test directly (Hydrated) or following dehydration for2 days (Dehydrated). When hydrated, the three groups of mice
ingested nearly equal amounts of water and hypertonic saline
(Figure 5B, Hydrated). When dehydrated, the mice injected
with the vehicle and control Ig preferred pure water and avoided
the hypertonic saline, and the preference ratio for 0.3 M NaCl
was markedly reduced (Figure 5B, Vehicle and Control Ig, Dehy-
drated). However, the mice injected with the patient’s Ig took
pure water and 0.3 M NaCl almost equally, and the preference
ratio for 0.3 M NaCl was not reduced (Figure 5B, Patient Ig,
Dehydrated). The total fluid intake was equally increased in the
three groups after dehydration (Figure 5C).
After the dehydration, the plasma [Na+] in the three groups
increased to the same level (Figure 5D, Dehydrated, i). In the
dehydrated strategy, the plasma [Na+] of mice injected with the
vehicle and control Ig recovered to the basal level at once in
the two-bottle test (Figure 5D, Vehicle and Control Ig, Dehy-
drated, ii, iii, and iv). In contrast, the plasma [Na+] of mice injected
with the patient’s Ig did not recover to the basal level soon under
the same condition, and remained at significantly high levels
during 1 week (Figure 5D, Patient Ig, Dehydrated, ii, iii, and iv).
Thus, injection of the patient’s Ig reproduced the persistent
hypernatremia in mice as observed in the patient.
Injection of Patient’s Ig Leads to Complement
Deposition and Infiltration of Inflammatory Cells
in Nax-Positive Regions in the Mouse Brain
Because some irreversible defects supposedly occurred in the
Nax-positive regions of the mice injected with the patient’s Ig
fraction, we next examined tissue damage of Nax-positive
regions in the mouse brain. First of all, we tried to detect deposi-
tion of the injected patient’s Ig in the Nax-positive regions of the
mouse brain. Brain sections were prepared from the mice 3 days
after the injection of the patient’s Ig, and were immunostained
with anti-human IgG antibody (Figure 6A). Significant signals
for human IgGwere found specifically in the Nax-positive regions
including the SFO and OVLT of the mice injected with the
patient’s Ig, but not of those injected with the control Ig. In con-
trast, no signal for human IgG was observed in the supraoptic
nucleus (SON), paraventricular nucleus (PVN), or choroid plexus,
where Nax is not expressed.
Because the human IgG1 subclass is known to activate
complement reactions (Mix et al., 2006),we thenexamineddepo-
sition of the complement component C3 in the brains of mice
injected with the patient’s Ig. It was clearly positive in the SFO
and OVLT where Nax is expressed (Figure 6B, Patient Ig), but
negative in the SON or PVN where Nax is not expressed. Impor-
tantly, choroid plexus, a place deficient in blood-brain barrier
(BBB) and Nax expression, was negative for C3 staining. On the
other hand, in the mice treated with control Ig, the C3 staining
was not detectable in any regions tested (Figure 6B, Control Ig).
These results suggested that complement was specifically
deposited where human Igs reacted with the relevant antigen.
It is well established that complement plays a detrimental role
in the acute inflammatory response following the attack on self-
tissues by autoantibodies (Tsokos, 2003). As was expected,
signals of CD68, a marker for reactive microglia and macro-
phages (Damoiseaux et al., 1994; Greaves and Gordon, 2002),
and the P2Y12 receptor, a specific marker for reactive microgliaNeuron 66, 508–522, May 27, 2010 ª2010 Elsevier Inc. 515
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Figure 5. Patient-Ig-Injected Mice Retained a High Plasma Na Level through Excessive Salt Intake in a Two-Bottle Test
(A) Experimental strategy for the two-bottle test. One week after the intravenous injection of either the Ig [from either the patient (Patient Ig) or the control subject
(Control Ig)] or saline (Vehicle), the mice underwent the two-bottle test with water and 0.3 M NaCl, directly (Hydrated) or following dehydration for 2 days (Dehy-
drated).
(B and C) Preference ratios for 0.3 M NaCl (B) and total intake volume (C) in the two-bottle test over 12 hr for the mice that received an intravenous injection of
Vehicle, Control Ig, or Patient Ig. The preference ratio was defined as the ratio of the volume of 0.3M saline ingested to total fluid intake. **p < 0.01 (compared with
Vehicle), ##p < 0.01 (compared with Control Ig), by two-tailed Mann-Whitney test; data are the mean and SE (n = 5 for each).
(D) Plasma Na+ levels of the mice just before (i), just after (ii), 24 hr after (iii), or 7 days after (iv) the two-bottle tests (see experimental strategy in A). *p < 0.05
and **p < 0.01 (compared with Vehicle), #p < 0.05 and ##p < 0.01 (compared with Control Ig), by two-tailed Mann-Whitney test; data are the mean and SE
(n = 5 for each).
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Autoimmunity to Na Sensor Causes Hypernatremia(Sasaki et al., 2003), were observed in the Nax-positive SFO,
OVLT, and posterior pituitary 3 days after the injection of the
patient’s Ig (Figure 6C; as for the ME, see Figure S6). In the
same mouse, however, the Nax-negative regions such as SON,
PVN, and choroid plexus were negative for these inflammatory
cells (data not shown). No signal for CD68 or P2Y12 was
observed in the mice injected with the control Ig (data not
shown).
Injection of Patient’s Ig Induces Cell Death
in Nax-Positive Regions in the Brain
Deposition of the C3 component and infiltration of inflammatory
cells are apparent signs of cytolysis within the Nax-positive
regions in the murine model. Thus, a major pathophysiological
feature in the mouse model appeared to be persistent focal
damage in the CVOs, the center for sensing the condition of
body fluids. So we assessed the cell death in the brains of the
mice 3 days after the injection of the patient’s Ig or the control
Ig. Complement-mediated cell death reportedly occurs through
both necrosis and apoptosis (Nauta et al., 2002).
For the detection of necrotic cell death, we performed propi-
dium iodide (PI) staining because necrotic cells in parenchyma
of the brain are reportedly stained by the intracerebroventricular
administration of PI (Unal Cevik and Dalkara, 2003). In the mice
injected with the patient’s Ig, we found significant cell death in516 Neuron 66, 508–522, May 27, 2010 ª2010 Elsevier Inc.the SFO and OVLT where Nax is expressed, but almost no cell
death in the SON, PVN, or choroid plexus where Nax is not
expressed (Figures 7A and 7C, Patient Ig). The number of
PI-positive cells in the SFO and OVLT was prominent in the
patient-Ig-injected mice compared with the control-Ig-injected
mice (Figure 7C). In the mice treated with the control Ig, PI-posi-
tive cells were scarcely detected in any of these regions (Figures
7A and 7C, Control Ig).
We also carried out terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) assays, which label
cells undergoing apoptosis and some forms of nonapoptotic
cell death (de Torres et al., 1997). TUNEL-positive cells were
also observed specifically in the Nax-positive SFO and OVLT
after the injection of the patient’s Ig, but not in Nax-negative
regions such as the SON, PVN, or choroid plexus (Figures 7B
and 7D, Patient Ig). Signals were not observed in any of these
regions in the mice injected with the control Ig (Figures 7B and
7D, Control Ig). Taken together with the PI-staining data, both
necrosis and apoptosis are evident in the Nax-expressing
regions of the CVOs in the mice injected with the patient’s Ig.
DISCUSSION
The association of hypernatremia with neurologic disorders has
been known for some time now, because the majority of patients
Neuron
Autoimmunity to Na Sensor Causes Hypernatremiawith essential hypernatremia have anatomic lesions in their CNS
to account for these abnormalities (Avioli et al., 1962; DeRubertis
et al., 1974; Welt, 1962). However, some cases were described
in the literature in which no demonstrable hypothalamic struc-
tural lesion was identified (Bappal et al., 2006; Cauble et al.,
2001; Conley et al., 1976; duRivage et al., 1985; Hayek and
Peake, 1982; Schaad et al., 1979). Intriguingly, the patients
reported so far as having essential (or adipsic) hypernatremia
without demonstrable intracranial lesions are all under 13 years
of age (4–12 years old). This finding has suggested the presence
of a distinct syndrome with altered hypothalamic function of
unknown etiology (Hayek and Peake, 1982). In the present study,
we identified a patient with essential hypernatremia without
a demonstrable intracranial lesion. In our patient, although the
symptoms became apparent in a short period before admission,
the hypernatremia had supposedly developed in a very insidious
manner, with mild to moderate elevations of the Na level and
without any remarkable symptoms at first. Then severe hyperna-
tremia became apparent enough to be symptomatic, probably
triggered by some factor or factors that influenced the amount
of water intake or amount of free water loss, such as perspira-
tion. The reason for this speculation is that the severity of her
symptoms is far milder than usually expected for acute and
remarkable elevations of the serum Na level. It’s striking that
in one case among the reports above, lethargy developed in
2 weeks after the patient caught a common cold (Conley
et al., 1976).
Of note is that our patient had a solid tumor adjacent to the
adrenal gland with a pathological diagnosis of ganglioneuroma
mainly composed of Nax-positive glial cells. Further, the patient
had autoantibodies against Nax, the Na-level sensor in the brain
involved in Na homeostasis (Noda, 2006, 2007). The passive
transfer of autoantibodies obtained from human patients to
animals has been used to establish models of autoimmune
etiology so far; for instance, myasthenic (and Lambert-Eaton)
syndrome (Lang et al., 1981; Takamori et al., 1994), cerebellar
ataxia (Sillevis Smitt et al., 2000), autoimmune autonomic
neuropathy (Vernino et al., 2004), and Pre-eclampsia (Zhou
et al., 2008). In the present study, mice injected with the patient’s
antibodies showed similar symptoms of hypernatremia, along
with deposits of the autoantibodies to Nax and C3 complement
factors, resulting in cell death specifically in the Nax-positive
brain regions. Importantly, the patient’s Ig fraction depleted
with autoantibodies to Nax did not induce the symptoms, indi-
cating that the autoantibodies are responsible for the disease.
Thus, this is the first model of hypernatremia based on autoim-
mune pathology classified as a PND. This mechanism may
contribute to a portion, if not all, of the pathological entity of
so-called essential hypernatremia (or adipsic hypernatremia)
without demonstrable hypothalamic structural lesion (Hayek
and Peake, 1982).
For hypernatremia, several potential pathogenetic mecha-
nisms are known (Ross and Christie, 1969). The most common
and simple cause of hypernatremia is the taking of excessive
salt, not enough water, or both (Adrogue´ and Madias, 2000).
When our patient stopped obligatory drinking of water for a few
days, her plasma Na level increased over 160 mM (Figure 1A;
for instance, day 84). This finding suggests that the patient isinclined to drink water insufficiently because of an absence of
thirst and is probably inclined to ingest excessive salt, leading
to a high plasma Na level. This abnormal behavior was repro-
duced in mice by passive transfer of the patient’s Ig (Figure 4).
The basal water intake of the patient-Ig-injectedmice under non-
feeding conditions was markedly small (Figure 4A). The patient-
Ig-injected mice did not avoid Na-rich food, even when dehy-
drated by water supply restriction (Figure 4E), similarly to the
Nax-KOmice (data not shown). Also,when thepatient-Ig-injected
mice were robustly dehydrated, they continued to ingest salt
water like the Nax-KO mice did, and their plasma [Na
+] did not
recover during the two-bottle preference test (Figure 5). This
abnormality in water/salt intake behavior would be one of the
causes of hypernatremia of the patient.
In addition to the altered water/salt intake behavior, the
patient-Ig-injectedmice showed a reduction in the plasma-vaso-
pressin response to dehydration (Figure 4B), which also resem-
bles a symptom of the patient (Figure 1E). However, of note, the
plasma vasopressin levels of Nax-KO mice are normal under
dehydrated conditions (Nagakura et al., 2010). This difference
between Nax-KO and patient-Ig-injected mice suggests that
autoantibodies to Nax not only affected the Na-level-sensing
mechanisms mediated by Nax channels, but also impaired the
regulatory systems for the production/release of vasopressin:
Nax is expressed in glial cells including the ependymal cell in
the SFO and OVLT (Watanabe et al., 2006). The SFO and OVLT
have projections to the SON and PVN, which are responsible
for the regulation of vasopressin (Mangiapane et al., 1984;
Thrasher et al., 1982). Osmosensors, e.g. TRPV1 and TRPV4,
are thought to be involved in the regulation of the activity of
these projection neurons in the SFO, OVLT, or both (Ciura and
Bourque, 2006; Liedtke et al., 2000). Histological damage to
the SFO and OVLT would be the reason for the dysregulation
of vasopressin production/release. In addition, damage to the
posterior pituitary, the site where vasopressin is released into
the blood circulatory system, would also affect the release.
This defect in the regulation of vasopressin appears to cause
a more serious symptom for the patient.
The possibility of irreversible deficits in Nax-positive loci,
including the SFO, OVLT, and posterior pituitary, was verified
by increased cell death in the mice 3 days after the injection of
the patient’s Ig (Figure 7). This notion was supported by not
only the deposition of the complement component C3, sugges-
tive of complement activation at these Nax-positive loci in the
mice (Figure 6B), but also the infiltration of inflammatory cells
with signals for CD68 and P2Y12 at the same loci (Figure 6C).
Furthermore, 14 days after the injection of the patient’s Ig,
we found that the SFO, OVLT, and posterior pituitary were
partially degenerated in some mice (data not shown). These
observations in the experimental animal model suggest that
the SFO, OVLT, and posterior pituitary were attacked by the
autoantibodies also in the patient. Supporting this view, C3
deposition and infiltration of CD68-positive inflammatory cells
were observed in the ganglioneuroma resected from the patient
(Figure S7).
The binding of an autoantibody to a target on the cell surface
has been known to trigger its internalization in cell-based assays
(i.e., muscle acetylcholine receptor antibodies in experimentalNeuron 66, 508–522, May 27, 2010 ª2010 Elsevier Inc. 517
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neuronal NMDA receptor antibodies in encephalitis [Dalmau
et al., 2008]). We found that the patient’s autoantibody induced
substantial internalization of Nax channels from the plasma
membrane of Nax-positive endogenous cells (Figures 3B and
3C) and C6 cells (see Supplemental Results and Figure S8).
Along with the internalization of Nax from C6 cells, the cellular
activities mediated by Nax, such as Na
+ influx and glucose
uptake activity, were also decreased (see Supplemental Results
and Figure S9).
The classical complement pathway is activated following
interaction of an antigen-antibody complex with C1 component
on the target cell surface. The pathway proceeds through the
cascade to ultimately produce the membrane attack complex
to lyse the cellular membrane. So it is conceivable that internal-
ization of the antigen-autoantibody complex interferes with the
progression of complement-mediated cell death. However, we
found that robust cell death is induced in the cell-based assay
using C6 cells by adding rabbit complement with the patient’s
serum, although this cytotoxic effect is indeed enhanced by
pharmacological inhibition of the internalization (see Supple-
mental Results and Figure S10). This complement-mediated
cell death likely occurred after one injection of the patient’s
Ig in the animal model, whereas it is probably ongoing in the
patient.
Although we could not detect any apparent lesions by cytol-
ysis in the CVOs or pituitary of the patient by MRI (Figure S2),
the damage to these loci is considered to be not minor because
the secretion of vasopressin in response to the patient’s hyper-
osmolar state was markedly impaired (Figure 1E). As shown in
Figure 2H, we found that the patient’s serum still contained
a certain amount of autoantibody to Nax even at 3 years and
4 years after the surgical removal of the Nax-positive tumor.
Although the obligatory dinking of water is safe and has been
effective in keeping the patient’s serum Na level around upper
normal levels to date, a trial to reduce or eliminate the autoanti-
body in our patient deserves consideration, in pursuit of a radical
cure of the disorder. Strategies include the autoantibody elimina-
tion by double-filtration plasmapheresis or immunoadsorption
therapy, and the administration of steroids, immunosuppres-
sants, or rituximab (anti-CD20 antibody), although careful moni-
toring of adverse events and approval by the appropriate ethics
committees are mandatory.
PNDs are a diverse group of diseases characterized by
neurologic dysfunction in the setting of a remote cancer (Darnell
and Posner, 2006). The term ‘‘paraneoplastic syndrome’’ refers
to symptoms or signs resulting from damage to organs or tissues
at locations remote from the primary site of a neoplasm or any of
its metastases. Here, the tumorigenesis is believed to initiate theFigure 6. Deposits of Complement and Infiltrates of Inflammatory Cells
(A) Immunostaining of the SFO, OVLT, SON, PVN, and choroid plexus with anti-h
mice 3 days after the injection of Control Ig or Patient Ig. OT, optic tract.
(B) Immunostaining of complement factor C3 and DAPI staining. Tissue sections
injection of Control Ig or Patient Ig are shown. OT, optic tract.
(C) Immunostaining of CD68 and P2Y12. Tissue sections of the SFO, OVLT, and p
DAPI staining shows the localization of cell nuclei in the section. See also Figuresyndrome by expressing a protein antigen normally expressed
in the nervous system, leading to antitumor immune responses
to induce autoimmune neurologic symptoms. The role of autoan-
tibodies in neurological disorders generally involves action on
the channel proteins. Such diseases are also referred to as
‘‘autoimmune channelopathies’’ (Vernino, 2007; Vincent et al.,
2006). Our study provides strong evidence for a novel PND in
which tumor cells extensively expressing Nax channels induced
the production of autoantibodies to Nax. Here, it is noteworthy
that nonmyelinating Schwann cells in the peripheral nervous
system (PNS) endogenously express Nax (Watanabe et al.,
2002). The primary targets of the autoantibodies involved in the
development of hypernatremia are most likely Nax-positive
ependymal cells, astrocytes, and pituicytes in the SFO, OVLT,
and posterior pituitary, which belong to the CVOs lacking
a BBB where antibodies easily leak from the blood vessels
(Broadwell and Sofroniew, 1993).
In summary, this study demonstrated for the first time that
a ganglioneuroma formed in the PNS triggered an autoimmune
channelopathy targeting Nax, the Na-level sensor of body fluids
in the brain, causing essential hypernatremia to develop. Patho-
genetically, autoantibodies to Nax likely induce persistent tissue
damage within the Nax-positive regions in the CVOs essential for
systemic water/salt homeostasis through the activation of
complement and infiltration of inflammatory cells.
EXPERIMENTAL PROCEDURES
Authorization for Human Subject Research
The research protocol was approved by the ethics committee of Tokai Univer-
sity School of Medicine and Bioethics Inquiry Committee of the National
Institute for Basic Biology. Informed consent was obtained from the subject’s
parents.
Experimental Animals
All the experiments with animals were carried out according to the guidelines
of the National Institute for Basic Biology. WT (C57BL/6J, CLEA Japan, Tokyo,
Japan) or homozygous Nax-KO males at 8–16 weeks of age were used for
experiments. The mice were housed in plastic cages under a constant room
temperature (23C) with a 12 hr light/dark cycle (lights on at 8:00 a.m.) with
ad libitum access to water and food (Rodent Diet CA-1, CLEA Japan).
Passive Transfer of the Ig Fraction into Mice
The Ig fraction was collected from the serum by precipitation with 33%
saturated ammonium sulfate followed by dialysis against normal saline.
In some experiments, Ig fraction was preabsorbed using peptide columns
(see Supplemental Experimental Procedures). Ig from the patient or a healthy
control subject was intravenously injected into WT mice (2.5 mg IgG in 200 ml
per 30 g body weight). The mice were used for the behavioral tests at 1 week
after the injection.
For the detailed procedures and the other methods, see the Supplemental
Information.Were Observed in the SFO and OVLT of the Patient-Ig-Injected Mice
uman IgG as the detection antibody. Brain tissue sections were prepared from
of the SFO, OVLT, SON, PVN, and choroid plexus of the mice 3 days after the
osterior pituitary of the mice 3 days after the injection of Patient Ig are shown.
S6 for the median eminence (ME). Scale bars in (A)–(C), 100 mm.
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Figure 7. Cell Death Was Observed in the SFO and OVLT of the Patient-Ig-Injected Mice
(A) Propidium Iodide (PI) staining in tissue sections of the SFO, OVLT, SON, PVN, and choroid plexus frommice 3 days after the injection of Control Ig or Patient Ig.
In the third row, magnified views of the squared regions in the SFO and OVLT are shown. OT, optic tract; scale bars, 100 mm.
(B) TUNEL staining in tissue sections of the SFO, OVLT, SON, PVN, and choroid plexus from mice 3 days after the injection of Control Ig or Patient Ig. OT, optic
tract; scale bars, 100 mm.
(C and D) Summary of PI (C) and TUNEL (D) assays. **p < 0.01 (compared with Control Ig in the same tissue region), by two-tailed t test; data are mean and SE of
three independent experiments.
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